64.80
+3.51%
Close of 9 Nov 2026, in NOK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Oncoinvent A
Its shares trade on Oslo Børs under the ticker ONCIN.OL. It has been listed since 13 December 2024. In the fiscal year to 31 December 2025, it reported revenue of NOK 28.1m and a net loss of NOK 155.1m. At that date it held total assets of NOK 205.0m and shareholders' equity of NOK 146.3m.
Oncoinvent ASA is a NO-based company operating in Pharmaceuticals industry. The company is headquartered in Oslo, Oslo. The company went IPO on 2024-12-13. Oncoinvent ASA is a Norway-based privately held radiopharmaceutical company. The firm is engaged in the development of alpha-emitting radiotherapeutics that provide better treatment options to cancer patients. The firm offers Radspherin, which is alpha-emitting radioactive microsphere therapy designed for the treatment of metastatic cancers in body cavities. The product candidate is a suspension of inorganic microspheres labelled with an alpha-emitting radioisotope for local administration. More specifically it consists of with calcium carbonate micro particles labelled with the radioisotope Radium-224d. The therapeutic goal is to treat residual micro metastases remaining after surgery in intracavitary surfaces and liquid without subjecting deeper regions of organs and tissues to harmful radiation doses.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 13 Dec 2024
- Employees
- 46
- Website
- oncoinvent.com ↗
Leadership
Pay as last reported
- Mr. Anders TullgrenNon-Executive Independent Chairman of the Board
- Mr. Olav HelleboChief Executive Officer
- Mr. Rune SkeieChief Financial OfficerNOK 3.3m
- Dr. James BarnesChief Operating OfficerNOK 3.7m
- Ms. Debbie MolyneuxChief People Officer
- Dr. Nigel MccrackenChief Scientific OfficerNOK 2.8m
- Ms. Gayle MillsChief Business Officer
- Ms. Cristina OliviaChief Medical Officer
- Dr. Gwyn ThomasInterim Head of Clinical Development
- Mr. David ColpmanNon-Executive Director
- Mr. Sveinung HoleNon-Executive Director, since 2016NOK 506,000
- Dr. Debra BarkerNon-Executive Independent DirectorNOK 320,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Oncoinvent ASA develops Radspherin for metastatic cancer treatment in body cavities.
- The company focuses on alpha-emitting radiotherapeutics for better cancer patient outcomes.
- Oncoinvent ASA employs 46 full-time staff in Oslo, Norway.
Weaknesses
- Oncoinvent ASA has no products approved for market use yet.
- The company's IPO occurred on 13 December 2024, limiting market experience.
- Oncoinvent ASA is a Norway-based company with limited global presence.
Opportunities
- Oncoinvent ASA can expand Radspherin use for additional cancer types.
- The growing demand for targeted cancer therapies presents a market opportunity.
- Oncoinvent ASA may seek partnerships with major pharmaceutical firms.
Threats
- Radspherin faces regulatory approval challenges in multiple countries.
- The company must navigate complex clinical trial requirements for alpha-emitting therapies.
- Competition from established cancer treatment providers remains a risk.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.